CTMC vs RoslinCT: CDMO Comparison
How does CTMC compare to RoslinCT for CAR-T manufacturing?
Side-by-side comparison of CTMC and RoslinCT on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- RoslinCT has FDA inspections on record (1); CTMC does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- RoslinCT maintains 1 MHRA / UK GMP certificate; CTMC does not.
- Composite Signal Score: RoslinCT 80/100 vs CTMC 63/100 — a 17-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both CTMC and RoslinCT qualify as CAR-T manufacturers; RoslinCT carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both CTMC and RoslinCT qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: CTMC vs RoslinCT
How does CTMC compare to RoslinCT for CAR-T manufacturing?
On CDMO Signal's composite Signal Score, CTMC is 63/100 and RoslinCT is 80/100; CTMC has 0 FDA inspections on record vs 1 for RoslinCT; European coverage is 0 active EMA+MHRA certificates for CTMC vs 1 for RoslinCT. Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, CTMC or RoslinCT?
Both CTMC and RoslinCT maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. CTMC has 0 FDA inspections on record; RoslinCT has 1.
How do CTMC and RoslinCT compare on European GMP coverage?
CTMC holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. RoslinCT holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for CAR-T manufacturing — CTMC or RoslinCT?
Both CTMC and RoslinCT are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
CTMC carries a Signal Score of 63/100 and RoslinCT carries 80/100 — a meaningful lead for RoslinCT. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →